Gynecologic Oncology · Nov 17, 2026
Glucagon-like peptide-1 receptor agonist use and overall survival in endometrial cancer: a multicenter propensity score–matched cohort study
By Yousif A, Elchouemi M, Asad AB
Objective To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and overall survival in women with endometrial cancer. Methods Using the TriNetX network, we identified women aged 18–75 years with endometrial cancer diagnosed between 2018 and 2024 and propensity score matched those with a GLP-1RA record within 12 months before diagnosis to women without prior use, with follow-up anchored to the date of diagnosis. A 2-year landmark analysis compared new GLP-1RA use within 2 years of diagnosis with no use among women alive at 2 years without evidence of advanced disease, and sensitivity analyses included an active comparator, race-stratified analyses and a negative-control outcome. The outcome was 5-year all-cause mortality. Results In the primary analysis (2646 matched pairs), 5-year survival was 91.6% among GLP-1RA users and 90.2% among non-users (hazard ratio [HR] 0.81; 95% confidence interval [CI], 0.65–1.02), and in the 2-year landmark analysis (2275 pairs) it was 96.4% and 96.3% (HR 0.92; 95% CI, 0.63–1.34). Results were similar against dipeptidyl peptidase-4 inhibitors (HR 0.91; 95% CI, 0.45–1.84) and by race (interaction P = 0.46), whereas a comparison with women who never received a GLP-1RA, as in previous studies, yielded an HR of 0.58 (95% CI, 0.48–0.70). Conclusions Once follow-up was anchored to the date of diagnosis, GLP-1RA use was not associated with significantly lower all-cause mortality in women with endometrial cancer, and these hypothesis-generating findings should temper the extrapolation of survival associations reported in other cancers until prospective trials are completed.